Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James C Evans

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
International Journal of Molecular Sciences|May 24, 2019
Development of a Bioluminescent BRCA1-Deficient Xenograft Model of Disseminated, High-Grade Serous Ovarian CancerYen Ting Shen, Lucy Wang, James C Evans, et al.
Molecular Pharmaceutics|May 12, 2018
BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell LinesYen Ting Shen, James C Evans, Gaetano Zafarana, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|December 2, 2017
Cyclodextrin-siRNA conjugates as versatile gene silencing agentsMeenakshi Malhotra, Matt Gooding, James C Evans, et al.
Journal of Pharmaceutical Sciences|March 19, 2021
Poly(δ-valerolactone-co-allyl-δ-valerolactone) cross-linked microparticles: Formulation, characterization and biocompatibilityZeqing Bao, Sungmin Jung, Jack Bufton, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|November 8, 2021
Turning down the heat: The case for mild hyperthermia and thermosensitive liposomesMaximilian Regenold, Pauric Bannigan, James C Evans, et al.
Molecular Pharmaceutics|December 29, 2017
Ratio-Dependent Synergism of a Doxorubicin and Olaparib Combination in 2D and Spheroid Models of Ovarian CancerSina Eetezadi, James C Evans, Yen-Ting Shen, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|December 12, 2022
Triggered release from thermosensitive liposomes improves tumor targeting of vinorelbineMaximilian Regenold, Kan Kaneko, Xuehan Wang, et al.
Scientific Reports|May 28, 2021
Heat-activated nanomedicine formulation improves the anticancer potential of the HSP90 inhibitor luminespib in vitroBrittany Epp-Ducharme, Michael Dunne, Linyu Fan, et al.
International Journal of Pharmaceutics|January 2, 2016
A novel, anisamide-targeted cyclodextrin nanoformulation for siRNA delivery to prostate cancer cells expressing the sigma-1 receptorKathleen A Fitzgerald, Meenakshi Malhotra, Matt Gooding, et al.
Journal of Pharmaceutical Sciences|March 8, 2014
Biophysical and structural characterisation of nucleic acid complexes with modified cyclodextrins using circular dichroismAoife M O'Mahony, Michael F Cronin, Anthony McMahon, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
International Journal of Molecular Sciences|May 24, 2019
Development of a Bioluminescent BRCA1-Deficient Xenograft Model of Disseminated, High-Grade Serous Ovarian CancerYen Ting Shen, Lucy Wang, James C Evans, et al.
Molecular Pharmaceutics|May 12, 2018
BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell LinesYen Ting Shen, James C Evans, Gaetano Zafarana, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|December 2, 2017
Cyclodextrin-siRNA conjugates as versatile gene silencing agentsMeenakshi Malhotra, Matt Gooding, James C Evans, et al.
Journal of Pharmaceutical Sciences|March 19, 2021
Poly(δ-valerolactone-co-allyl-δ-valerolactone) cross-linked microparticles: Formulation, characterization and biocompatibilityZeqing Bao, Sungmin Jung, Jack Bufton, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|November 8, 2021
Turning down the heat: The case for mild hyperthermia and thermosensitive liposomesMaximilian Regenold, Pauric Bannigan, James C Evans, et al.
Molecular Pharmaceutics|December 29, 2017
Ratio-Dependent Synergism of a Doxorubicin and Olaparib Combination in 2D and Spheroid Models of Ovarian CancerSina Eetezadi, James C Evans, Yen-Ting Shen, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|December 12, 2022
Triggered release from thermosensitive liposomes improves tumor targeting of vinorelbineMaximilian Regenold, Kan Kaneko, Xuehan Wang, et al.
Scientific Reports|May 28, 2021
Heat-activated nanomedicine formulation improves the anticancer potential of the HSP90 inhibitor luminespib in vitroBrittany Epp-Ducharme, Michael Dunne, Linyu Fan, et al.
International Journal of Pharmaceutics|January 2, 2016
A novel, anisamide-targeted cyclodextrin nanoformulation for siRNA delivery to prostate cancer cells expressing the sigma-1 receptorKathleen A Fitzgerald, Meenakshi Malhotra, Matt Gooding, et al.
Journal of Pharmaceutical Sciences|March 8, 2014
Biophysical and structural characterisation of nucleic acid complexes with modified cyclodextrins using circular dichroismAoife M O'Mahony, Michael F Cronin, Anthony McMahon, et al.
Pageof 3